Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD201 vs Herceptin in HER2+ Early Breast Cancer
NCT03013504Phase 3Completed
- Sponsor
- Prestige Biopharma Limited
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of coprelotamab in breast cancer (2 arms), sponsored by Prestige Biopharma Limited. Primary endpoint: Total Pathological Complete Response Rate at 24 weeks. Started Feb 2018; status: completed.
02
Drugs
coprelotamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03013504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013504.